HIV Medication Adherence Clinical Trial
— STARTOfficial title:
Controlled Evaluation of the Adherence Readiness Program for ART Adherence
NCT number | NCT02329782 |
Other study ID # | MH104086 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2015 |
Est. completion date | March 30, 2020 |
Verified date | October 2020 |
Source | RAND |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Multi-site, randomized controlled trial of the Adherence Readiness Program (ARP) adherence intervention for HIV clients starting or restarting antiretroviral therapy (ART) for the purpose of achieving and sustaining optimal levels of ART adherence and virologic suppression. Eligible participants will be randomized to receive either the ARP intervention or usual care (no intervention) and followed for 24 months.
Status | Completed |
Enrollment | 240 |
Est. completion date | March 30, 2020 |
Est. primary completion date | March 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. The patient's provider views the patient as medically appropriate to begin (ART naïve) or restart ART (has been off ART for at least 2 months), and either - plans to start the patient on ART - would like to start the patient on ART but the provider or patient is uncertain about the patient's readiness to adhere well. Patients who are currently on ART are also eligible if they meet the following criteria, which are specific only to this type of patient: i) the patient has 2 or more HIV viral load tests in the past year > 1000 copies/ml ii) the patient has had no HIV viral load tests that were undetectable in the past year iii) the patient has a genotype in the past year that does not show resistance as a reason for virologic failure (detectable viral load) iv) primary care provider views the patient as a good candidate for the study, with the understanding that the patient will interrupt ART if assigned to the intervention. Criteria i to iii are intended to define a subgroup of nonadherent patients who are taking very little of their ART medications, as evidenced by the combination of consistently high viral load and no drug resistance. If the patient was taking at least a moderate level of drug and still had consistently high viral load, than they would have evidence of drug resistance. Providers are generally comfortable with this type of patient stopping their medication in order to facilitate the pre-treatment, adherence readiness assessment and training phase of the intervention prior to restarting the patient on treatment. 2. The patient's health status is stable. There is no current acute OI or medical condition that calls for immediate ART, as determined by the patient's provider. 3. Most recent HIV viral load is detectable. 4. If CD4 < 200, the patient is on or will be prescribed prophylactic medication 5. Patient is 18 or older. 6. Patient is able and willing to give informed consent. 7. English speaking. Exclusion Criteria: 1. Patient just tested HIV+ and their provider suspects the patient may be acutely or recently infected (within past 6 months). |
Country | Name | City | State |
---|---|---|---|
United States | CARE CLinic | Long Beach | California |
United States | T.H.E. Clinic | Los Angeles | California |
United States | UCLA Care Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
RAND | Long Beach Education and Research Consultants, University of California, Los Angeles |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HIV virologic suppression | undetectable HIV viral load at time of assessment | Month 24 | |
Primary | log change in HIV viral load (log change in HIV RNA levels) | log change in HIV RNA levels from baseline to Month 24. | Month 24 | |
Primary | optimal dose-taking adherence (whether at least 85% of prescribed doses were taken) | binary variable representing whether at least 85% of prescribed doses were taken between baseline and Month 24 | Month 24 | |
Primary | percent dose-taking adherence | percent of prescribed doses taken between baseline and Month 24 | Month 24 | |
Primary | HIV virologic suppression | undetectable HIV viral load at time of assessment | Month 6 | |
Primary | log change in HIV viral load (log change in HIV RNA levels) | log change in HIV RNA levels from baseline to Month 6 | Month 6 | |
Primary | optimal dose-taking adherence (whether at least 85% of prescribed doses were taken) | binary variable representing whether at least 85% of prescribed doses were taken between baseline and Month 6 | month 6 | |
Primary | percent dose-taking adherence | percent of prescribed doses taken between baseline and Month 6 | month 6 | |
Secondary | dose-timing adherence | percent of prescribed doses taken within correct time-window between baseline and Month 24 | Month 24 | |
Secondary | dose-timing adherence | percent of prescribed doses taken within correct time-window between baseline and Month 6 | Month 6 | |
Secondary | optimal dose-timing adherence | binary variable representing whether at least 85% of prescribed doses were taken within correct time-window between baseline and Month 24 | Month 24 | |
Secondary | optimal dose-timing adherence | binary variable representing whether at least 85% of prescribed doses were taken within correct time-window between baseline and Month 6 | Month 6 | |
Secondary | change in CD4 count | change in CD4 count from baseline to Month 24 | Month 24 | |
Secondary | change in CD4 count | change in CD4 count from baseline to Month 6 | Month 6 | |
Secondary | clinic attendance (number of missed clinic appointments) | number of missed clinic appointments between baseline and Month 24 | Month 24 | |
Secondary | clinic attendance (number of missed clinic appointments) | number of missed clinic appointments between baseline and Month 6 | Month 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01122186 -
Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE)
|
N/A |